Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

Senator Chuck Schumer introduced a federal marijuana legalization bill.  Members of Congress exchanged views with the U.S. Anti-Doping Agency over cannabis and the Olympics. Tennessee took a first step towards legalization.  Cannabis research could be protected in new legislation.  And finally,
Continue Reading The Week in Weed: July 16, 2021

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

Federal legislation to legalize cannabis is under consideration.  In state news, Virginia moved up its timeline to legalize possession and home grow.  New York launched a cannabis control website.  We take a look at what’s happening in Montana.  South Carolina probably
Continue Reading The Week in Weed: April 9, 2021

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

We bring you an update on Virginia and New Jersey.  New bills appear in New Mexico and Minnesota.  Lawsuits hover over the rollout of legalized marijuana in South Dakota and Mississippi.  Will an amendment banning future legalization succeed in Idaho? Democratic
Continue Reading The Week in Weed: February 5, 2021

This is Washington, and we do like to speak in initials.  A plain English translation of the title of this piece would read “FDA ‘places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in Schedule V.’”  DEA Final Order, Docket No. DEA-486 Schedule V drugs include cough medicine with codeine and many pain relievers that still require a prescription.  So, really what this order does is allow doctors in the US legally to prescribe the recently approved epilepsy drug, Epidiolex, and allows pharmacies, rather than marijuana dispensaries, legally to sell the drug.
Continue Reading FDA: .1% CBD OK

On June 25, 2018, the Food and Drug Administration (“FDA”) approved Epidiolex (cannabidiol), the first marijuana derived drug for use in the United States, to treat two rare forms of epilepsy. This decision for the FDA could have sweeping effects for the marijuana industry. While the FDA has previously approved drugs comprising synthetic (manufactured) cannabinoids, this is the first FDA approved drug comprised of an active ingredient derived from marijuana. Even with FDA approval, further action is required before Epidiolex can enter the market in the United States.


Continue Reading FDA Approves First Marijuana-Based Drug to Treat Epilepsy